Co-Diagnostics, Inc. Announces Completion of the Acquisition of all Assets and Intellectual Property Related to At-Home/Point-of-Care Platform
SALT LAKE CITY, Dec. 31, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has completed the acquisition of Idaho Molecular Inc. and Advanced Conceptions, Inc. for nearly 4.72 million shares of the Company's stock, plus additional common warrants totaling 465,000, providing Co-Diagnostics with all existing and future assets and intellectual property related to the Company's upcoming at-home/point-of-care diagnostic device.
